Androgenetic alopecia (AGA) is the most common type of hair loss. The relatively strong concordance of the degree of baldness in fathers and sons is not consistent with a simple Mendelian trait, and a polygenic basis is considered to be most likely. So far, the predisposing genes for AGA are unknown and we do not understand the molecular steps involved in androgen-dependent beard growth versus androgen-dependent hair loss, but AGA can be defined as a dihydrotestosterone (DHT)-dependent process with continuous miniaturization of sensitive hair follicles. The type 2 5α-reductase plays a central role by the intrafollicular conversion of testosterone to DHT. However, due to the increasing knowledge in this field, we now know that there are many more steroidogenic enzymes involved in the onset and development of AGA, and this article shall provide a critical overview of recent discoveries.

Keywords:
Hair, Hair loss, Androgens, Androgen metabolism
1.
Hamilton JB: Male hormone stimulation as a prerequisite and an incitement in common baldness. Am J Anat 1942;71:451–453.
2.
Sperling LC, Heimer WL II: Androgen biology as a basis for the diagnosis and treatment of androgenic disorders in women. Part I. J Am Acad Dermatol 1993;28:669–683.
3.
Tenniswood M, Abrahams P, Winterton V, Bird CE, Clark AF: Binding of testosterone, 5 alpha-dihydrotestosterone and 5 alpha-androstane (3 alpha- and 3 beta-), 17 beta-diols to serum proteins in the rat. J Steroid Biochem 1982;16:617–620.
4.
Van Scott EJ, Ekel TM: Geometric relationships between the matrix of the hair bulb and its dermal papilla in normal and alopecic scalp. J Invest Dermatol 1958;31:281–287.
5.
Whiting DA: Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001;45:S81–S86.
6.
Cowper SE, Rosenberg AS, Morgan MB: An investigation of apoptosis in androgenetic alopecia. Am J Dermatopathol 2002;24:204–208.
7.
Sawaya ME, Keane RW, Blume-Peytavi U, Mullins DL, Nusbaum BP, Whiting D, Nicholson DW: Androgen responsive genes as they affect hair growth. Eur J Dermatol 2001;11:304–308.
8.
Prieto VG, Sadick NS, Shea CR: Androgenetic alopecia: Analysis of proliferation and apoptosis. Arch Dermatol 2002;138:1101–1102.
9.
Steinberger E, Smith KD, Rodriguez-Rigau LJ: Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women. J Clin Endocrinol Metab 1984;59:471–477.
10.
Pitts RL: Serum elevation of dehydroepiandrosterone sulfate associated with male pattern baldness in young men. J Am Acad Dermatol 1987;16:571–573.
11.
Dijkstra AC, Vermeesch-Markslag AM, Vromans EW, Happle R, van de Kerkhof PC, Zwanenburg B, Vos F, Vermorken AJ: Substrate specific sulfatase activity from hair follicles in recessive X-linked ichthyosis. Acta Derm Venereol 1987;67:369–376.
12.
Hoffmann R, Rot A, Niiyama S, Billich A: Steroid sulfatase activity in the human hair follicle concentrates in the dermal papilla – Possible involvement in local androgen metabolism. J Invest Dermatol 2001;117:1342–1348.
13.
Hodgins MB, Murad S, Simpson NB: A search for variation in hair follicle androgen metabolism which might be linked to male pattern baldness (abstract). Br J Dermatol 1985;113:794.
14.
Nowakowski H, Lenz W: Genetic aspects of male hypogonadism. Prog Horm Res 1961;17:53–89.
15.
Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159–161.
16.
Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW: Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992;90:799–809.
17.
Thigpen AE, Davis DL, Gautier T, Imperato-McGinley J, Russell DW: Brief report: The molecular basis of steroid 5 alpha-reductase deficiency in a large Dominican kindred. N Engl J Med 1992;327:1216–1219.
18.
Takashima I, Montagna W: Studies of common baldness of the stump-tailed macaque (Macaca speciosa). VI. The effect of testosterone on common baldness. Arch Dermatol 1971;103:527–534.
19.
Sawaya ME: Steroid chemistry and hormone controls during the hair follicle cycle. Ann NY Acad Sci 1991;642:376–383, discussion 383–374.
20.
Itami S, Kurata S, Sonoda T, Takayasu S: Mechanism of action of androgen in dermal papilla cells. Ann NY Acad Sci 1991;642:385–395.
21.
Itami S, Kurata S, Sonoda T, Takayasu S: Characterization of 5 alpha-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Dermatol 1991;96:57–60.
22.
Hoffmann R, Happle R: Finasteride is the main inhibitor of 5α-reductase activity in microdissected dermal papillae of human hair follicles. Arch Dermatol Res 1999;291:100–103.
23.
Sawaya ME, Price VH: Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296–300.
24.
Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J: Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1995;1:287–294.
25.
Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R: 17α-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol 2002;11:376–380.
26.
Randall VA, Thornton MJ, Hamada K, Messenger AG: Androgen action in cultured dermal papilla cells from human hair follicles. Skin Pharmacol 1994;7:20–26.
27.
Wahe M, Antonipillai I, Horton R: Effects of transforming growth factor beta and epidermal growth factor on steroid 5 alpha-reductase activity in genital skin fibroblasts. Mol Cell Endocrinol 1993;98:55–59.
28.
Horton R, Pasupuletti V, Antonipillai I: Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology 1993;133:447–451.
29.
Dykstra KD, Payne AM, Abdelrahim M, Francis GL: Insulin-like growth factor 1, but not growth hormone, has in vitro proliferative effects on neonatal foreskin fibroblasts without affecting 5-alpha-reductase or androgen receptor activity. J Androl 1993;14:73–78.
30.
Arai A, von Hintzenstern J, Kiesewetter F, Schell H, Hornstein OP: In vitro effects of testosterone, dihydrotestosterone and estradiol on cell growth of human hair bulb papilla cells and hair root sheath fibroblasts. Acta Derm Venereol 1990;70:338–341.
31.
Yu DW, Yang T, Sonoda T, Gaffney K, Jensen PJ, Dooley T, Ledbetter S, Freedberg IM, Lavker R, Sun TT: Message of nexin 1, a serine protease inhibitor, is accumulated in the follicular papilla during anagen of the hair cycle. J Cell Sci 1995;108:3867–3874.
32.
Sonoda T, Kurata S, Asada Y, Takayasu S: Message of protease nexin-1 is expressed in human dermal papilla cells and is affected by androgens (abstract). J Invest Dermatol 1998;100:612.
33.
Itami S, Sonoda T, Kurata S, Takayasu S: Mechanism of action of androgen in hair follicles. J Dermatol Sci 1994;7(suppl):S98–S103.
34.
Obana N, Chang C, Uno H: Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque. Endocrinology 1997;138:356–361.
35.
Thornton MJ, Hamada K, Messenger AG, Randall VA: Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. J Invest Dermatol 1998;111:727–732.
36.
Hibberts NA, Messenger AG, Randall VA: Dermal papilla cells derived from beard hair follicles secrete more stem cell factor (SCF) in culture than scalp cells or dermal fibroblasts. Biochem Biophys Res Commun 1996;222:401–405.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.